ResMed Inc. (RMD)
ResMed, Inc. engages in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its product portfolio includes obstructive sleep apnea, and other respiratory disorders that occur during sleep. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
|Market Price at 17-11-2017
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference ResMed Inc.:
Thursday, January 30, 2014
Reports for around 300 global stocks flowed through Skaffold during January, including Apple, Microsoft, Procter and Gamble, AT&T, Facebook, Intel, The Boeing Company, eBay, Nike, Caterpillar, Starbucks, Kimberly Clark, Yahoo!, Motorola, Xerox, Oshkosh, The Bank of Nova Scotia, Metro Inc, Prada, Singapore Exchange, PZ Cussons and SGS Societe Generale de Surveillance.
Exclusively for Skaffold members, we’ve put together a list of companies whose latest financial results are now available in Skaffold, including updated Skaffold Scores and Safety Margins.
Friday, November 08, 2013
ResMed recently released its quarterly results. Recent changes to the US Medicare laws have meant significantly lower reimbursement rates for ResMed’s products. While this disruption in the market was anticipated and widely known, the fall in Resmed’s sales was greater than expected.
Skaffold’s founder Roger Montgomery recently shared his thoughts on ResMed’s future and suggested that investors ask themselves this important question:
“Is the issue permanent or merely a temporary one that is being treated as permanent by a bi-polar Mr Market?”
Thursday, August 22, 2013
ResMed recently announced a record year for revenue and income. The fourth quarter an especially successful period for the company.
While expenses rose over the last year, this was more than offset by the increase in revenue and income.
ResMed continues to enjoy strong earnings growth and its value is currently forecast to rise over the next 2 years. The company also declared a dividend for the year, something they have not done over the last 10 years.
Thursday, May 02, 2013
ResMed has been a hot topic at Skaffold lately, partly because the company recently released its third quarter results to the NYSE. Some market commenters have gone so far as to liken ResMed to Australian greats Cochlear (COH) and CSL. ResMed’s business fundamentals have shown strong performance recently, and Skaffold suggests future growth in intrinsic value of more than 16% per annum.
Whilst the market price of US$48 is well above today’s intrinsic value estimate of close to US$30, and even the 2015 estimate of circa $41.50, given RMD’s strong track record and future growth prospects, it may be a stock worth keeping an eye on in case a price correction should occur in the future.